Crispr Therapeutics AG

Crispr Therapeutics AG is a biotechnology company specializing in the development of gene-editing therapies using the CRISPR/Cas9 platform. Its primary mission is to create transformative medicines that address serious genetic and chronic diseases. The company’s portfolio includes both approved and investigational therapies, notably pioneering treatments for blood disorders such as sickle cell disease and β-thalassemia. Crispr Therapeutics AG's leading therapy, developed in partnership with Vertex Pharmaceuticals, has achieved regulatory approval in several countries, representing a historic milestone for CRISPR-based medicines. Beyond hemoglobinopathies, its research and pipeline encompass a range of indications including oncology, autoimmune diseases, and type 1 diabetes. Headquartered in Zug, Switzerland, with research and manufacturing facilities in the US and Europe, Crispr Therapeutics AG is highly regarded for its scientific leadership, innovation, and dedication to advancing gene-based medical solutions that have the potential to address unmet medical needs on a global scale.